# Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

> **NCT02823106** · PHASE1 · WITHDRAWN · sponsor: **Justin Fraser**

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Verapamil and Citicoline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02823106
- **Lead sponsor:** Justin Fraser
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study put on clinical hold by FDA. Sponsor decided to no pursue the study.
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823106, "Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02823106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*